Last reviewed · How we verify

Corticosteroid with lidocaine with epinephrine

Vanderbilt University Medical Center · FDA-approved active Small molecule Quality 5/100

Corticosteroid with lidocaine with epinephrine, marketed by Vanderbilt University Medical Center, holds a niche position in the pharmaceutical market. The key composition patent expires in 2028, providing a competitive advantage through exclusive formulation rights. The primary risk is the lack of reported revenue and key trial results, which may limit market visibility and investor confidence.

At a glance

Generic nameCorticosteroid with lidocaine with epinephrine
SponsorVanderbilt University Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: